One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Erythropoietic Protoporphyria. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
The FDA is expected to decide on Dersimelagon for Erythropoietic protoporphyria and X-linked protoporphyria by the end of February 2027, under an NDA from LEO Pharma.
What the FDA is deciding on Dersimelagon for Erythropoietic Protoporphyria
The FDA is reviewing LEO Pharma's application to approve Dersimelagon for erythropoietic protoporphyria and X-linked protoporphyria.
Once-daily oral MC1R agonist under Priority Review for EPP and XLP, the rare inherited disorders in which protoporphyrin builds up in red blood cells and sunlight causes pain within minutes. It works through the same skin-pigment receptor as Scenesse, the only approved treatment, which is an implant placed every 2 months and is approved for adults only; dersimelagon was studied from age 12.
In the Phase 3 INSPIRE trial of 165 people, it added 23.19 minutes a day of sunlight before the first warning symptom compared with placebo (p=0.004) and cut total pain events by 39%. Developed by Tanabe Pharma, which submitted the NDA in June 2026; LEO Pharma announced on September 18, 2026 that the FDA had accepted the NDA with Priority Review and that the acquisition had closed.
LEO has disclosed only that the action date falls by the end of February 2027.
Who the Dersimelagon decision matters to
Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare inherited disorders in which a light-sensitive chemical called protoporphyrin builds up in red blood cells and skin, so sunlight causes tingling, burning and then severe pain within minutes, usually without blisters. A minority develop gallstones or liver damage.
Scenesse (afamelanotide), an implant placed under the skin every 2 months, is the only FDA-approved treatment and is for adults. A once-daily pill, dersimelagon, is under FDA review with a decision expected by the end of February 2027; a second pill, bitopertin, met every goal of its Phase 3 trial on October 19, 2026 and is headed back to the FDA; and a third, PORT-77, is recruiting.
Prevalence: NORD estimates EPP affects about 1 in 75,000 to 1 in 200,000 people in Europe and says the number in the US is unknown. Clinuvel cites a figure of 1 in 140,000 from a 2016 FDA workshop, which would be roughly 2,300 people in the US. XLP accounts for about 10% of cases in the US, according to NORD and a study of 226 North American patients, in which 9.7% had XLP. See our full Erythropoietic Protoporphyria page for current treatments, recruiting trials, and community resources.
How Dersimelagon works
Dersimelagon: oral, non-peptide small molecule that selectively activates the melanocortin 1 receptor (MC1R) on pigment cells, increasing melanin and the skin's tolerance of light. Our full Dersimelagon profile covers how it works, side effects in plain language, and its trial history.
What an approval or a rejection of Dersimelagon would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.
Where Erythropoietic Protoporphyria treatment stands today
Read our full Erythropoietic Protoporphyria treatment summary
Every late-stage EPP program is an oral drug, and 3 are in motion. Dersimelagon, which like Scenesse darkens skin through the MC1R receptor, met its Phase 3 INSPIRE goal and is under FDA priority review with a decision expected by the end of February 2027.
Bitopertin, which lowers protoporphyrin production in the bone marrow, got a complete response letter in February 2026 because its earlier trials did not tie the protoporphyrin drop to more pain-free sunlight.
On October 19, 2026 Disc Medicine reported that the Phase 3 APOLLO trial met both of its main goals: protoporphyrin fell 41.4% more than on placebo and people gained 12.2 more hours a month in light without pain during the sixth month.
Disc plans to resubmit to the FDA by the end of 2026 and expects a decision by mid-2027; APOLLO is closed, and the only route to the drug now is the US expanded access program for ages 12 and up. PORT-77, which blocks the transporter that moves protoporphyrin out of red cells, is recruiting people aged 12 and up at US sites for its Phase 2b/3 PATHWAY trial.
Bring your red cell protoporphyrin and gene results to the first call; trials require both, and most exclude anyone who had a Scenesse implant in the past 2 to 3 months.
The Erythropoietic Protoporphyria page has every treatment and trial →Meanwhile, 2 Erythropoietic Protoporphyria studies are recruiting or not yet recruiting
Whatever the FDA decides here, research on Erythropoietic Protoporphyria does not stop. Of these, 1 tests a treatment; the others follow patients over time. The most recently updated:
Earlier-stage drugs Trial Friend tracks for Erythropoietic Protoporphyria
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Erythropoietic Protoporphyria. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.
We never share your email. Stop anytime from the link in every email. Privacy policy
Frequently asked questions
When is the FDA decision on dersimelagon for EPP?
By the end of February 2027, according to LEO Pharma.
Status: LEO Pharma announced on September 18, 2026 that the FDA had accepted the NDA with Priority Review.
Exact date: not disclosed.
Source: LEO Pharma, September 18, 2026
Did dersimelagon work in its Phase 3 trial?
Yes. INSPIRE met its primary endpoint and its key secondary endpoints.
Trial: 165 people aged 12 to 75 with EPP or XLP, 200mg once daily or placebo for 16 weeks.
Main result: 23.19 more minutes a day of sunlight before the first warning symptom during weeks 12 to 16 (p=0.004), 29.64 minutes at week 16.
Also: 39% fewer total pain events (p=0.004); Patient Global Impression of Change difference of -1.83 (p<0.001).
Side effects more common than placebo: new moles, headache, nausea, diarrhea, skin darkening.
Source: Tanabe Pharma, March 30, 2026
Would dersimelagon replace the Scenesse implant?
It would be a second option with the same receptor target, taken as a daily pill instead of an implant every 2 months.
Ages: studied from age 12; Scenesse is approved for adults only, so it could become the first treatment for adolescents.
Head to head: no trial has compared the 2.
Source: Tanabe Pharma, March 30, 2026; Scenesse prescribing information
When will the FDA decide on Dersimelagon?
LEO Pharma expects a decision by the end of February 2027 but has not given an exact date.
Who disclosed it: LEO Pharma. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
What is Dersimelagon being reviewed for?
LEO Pharma submitted an NDA for Dersimelagon in Erythropoietic protoporphyria and X-linked protoporphyria.
What to know: Once-daily oral MC1R agonist under Priority Review for EPP and XLP, the rare inherited disorders in which protoporphyrin builds up in red blood cells and sunlight causes pain within minutes. It works through the same skin-pigment receptor as Scenesse, the only approved treatment, which is an implant placed every 2 months and is approved for adults only; dersimelagon was studied from age 12. In the Phase 3 INSPIRE trial of 165 people, it added 23.19 minutes a day of sunlight before the first warning symptom compared with placebo (p=0.004) and cut total pain events by 39%. Developed by Tanabe Pharma, which submitted the NDA in June 2026; LEO Pharma announced on September 18, 2026 that the FDA had accepted the NDA with Priority Review and that the acquisition had closed. LEO has disclosed only that the action date falls by the end of February 2027.
How it works: Oral, non-peptide small molecule that selectively activates the melanocortin 1 receptor (MC1R) on pigment cells, increasing melanin and the skin's tolerance of light.
More: the Dersimelagon drug page explains it in plain language.
Is there already an FDA-approved treatment for Erythropoietic Protoporphyria?
Yes. Trial Friend's drug list includes 1 FDA-approved drug for Erythropoietic Protoporphyria.
Approved: Scenesse (afamelanotide).
Also coming: Bitopertin.
Check: the Erythropoietic Protoporphyria page also searches FDA drug labels for approved treatments.
What did the Dersimelagon trials show?
INSPIRE (NCT06144840) was a global, randomized, double-blind, placebo-controlled Phase 3 trial in 165 people aged 12 to 75 with EPP or XLP. The primary endpoint was the average daily time in sunlight before the first prodromal symptom (tingling, stinging or burning) during weeks 12 to 16. Dersimelagon beat placebo by a least-squares mean difference of 23.19 minutes a day (p=0.004), and by 29.64 minutes at week 16 in a supplementary analysis (p=0.004).
More: the Dersimelagon drug page has the full trial history and sources.
What are the side effects of Dersimelagon?
Tanabe reported that dersimelagon was generally well tolerated in INSPIRE, with a safety profile consistent with its mechanism. The most common adverse events that occurred more often than with placebo were melanocytic nevi (benign moles), headache, nausea, diarrhea and skin hyperpigmentation.
More: the Dersimelagon drug page has the safety details reported so far.
Can I get Dersimelagon before the FDA decides?
Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.
Trials: 2 Erythropoietic Protoporphyria studies are recruiting or not yet recruiting, 1 of them testing a treatment. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask LEO Pharma directly. Registered programs are listed on ClinicalTrials.gov.
How much will Dersimelagon cost?
LEO Pharma has not announced a price. Drugmakers usually set it around approval.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Dersimelagon decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from LEO Pharma announcement, September 18, 2026. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.